KR950032279A - 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna) - Google Patents

인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna) Download PDF

Info

Publication number
KR950032279A
KR950032279A KR1019950004069A KR19950004069A KR950032279A KR 950032279 A KR950032279 A KR 950032279A KR 1019950004069 A KR1019950004069 A KR 1019950004069A KR 19950004069 A KR19950004069 A KR 19950004069A KR 950032279 A KR950032279 A KR 950032279A
Authority
KR
South Korea
Prior art keywords
polypeptide
seq
dna
set forth
sequence set
Prior art date
Application number
KR1019950004069A
Other languages
English (en)
Other versions
KR100391227B1 (ko
Inventor
다스쿠 혼조
야스마사 이시다
다카시 시노하라
Original Assignee
다스쿠 혼조
우에노 도시오
오노 야쿠힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다스쿠 혼조, 우에노 도시오, 오노 야쿠힝 고교 가부시키가이샤 filed Critical 다스쿠 혼조
Publication of KR950032279A publication Critical patent/KR950032279A/ko
Application granted granted Critical
Publication of KR100391227B1 publication Critical patent/KR100391227B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 인체 프로그램된 세포 사멸과 관련있는 막 단백질(PD-1) 및 상기 단백질을 암호하는 신규 DNA에 관한 것이다. PD-1 단백질은 각종 감염, 면역학적 억제 또는 상승, 또는 암 등의 치료에 유용할 수 있다.

Description

인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(DNA)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 상당히 정제된 형태의 서열 번호 1에 제시된 아미노산 서열을 갖는 폴리펩티드, 그 상동체 또는 그 서열의 단편 또는 단편의 상동체.
  2. 제1항에 있어서, 서열 번호 1에 제시된 아미노산 서열을 갖는 폴리펩티드.
  3. 제1항에 따른 폴리펩티드를 암호하는 DNA.
  4. 제3항에 있어서, 서열 번호 2에 제시된 누클레오티드 서열 또는 서열 번호 2에 선택적으로 하이브리드 할 수 있는 그 단편을 갖는 DNA.
  5. 제3항에 있어서, 서열 번호 3에 제시된 누클레오티드 서열 또는 서열 번호 3에 선택적으로 하이브리드 할 수 있는 그 단편을 갖는 DNA.
  6. 제3항 내지 제5항중 어느 한 항에 따른 DNA를 함유하는 복제 및 형질발현 벡터.
  7. 제6항에 따른 복제 및 형질발현 벡터로 형질전환 또는 형질감염된 숙주 세포.
  8. 제1항 또는 제2항에 따른 폴리펩티드를 형질발현시키기에 효과적인 조건하에서 제7항에 따른 숙주 세포를 배양하는 것을 포함하는 폴리펩티드를 생산하는 방법.
  9. 제1항 또는 제2항에 따른 폴리펩티드에 대한 모노클로날 또는 폴리클로날 항체.
  10. 약학적 허용 희석제 및/또는 담체와 함께, 제1항 또는 제2항에 따른 폴리펩티드, 또는 제9항에 따른 항체를 함유하는 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950004069A 1994-03-01 1995-02-28 인체의 프로그램화 된 세포사멸과 관련있는 펩티드 및 이를 암호하는 디엔에이(dna) KR100391227B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP94-55224 1994-03-01
JP94-055224 1994-03-01
JP5522494 1994-03-01

Publications (2)

Publication Number Publication Date
KR950032279A true KR950032279A (ko) 1995-12-20
KR100391227B1 KR100391227B1 (ko) 2003-10-22

Family

ID=12992645

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950004069A KR100391227B1 (ko) 1994-03-01 1995-02-28 인체의 프로그램화 된 세포사멸과 관련있는 펩티드 및 이를 암호하는 디엔에이(dna)

Country Status (6)

Country Link
US (2) US5629204A (ko)
EP (1) EP0670369A3 (ko)
JP (2) JPH07291996A (ko)
KR (1) KR100391227B1 (ko)
CN (1) CN1080311C (ko)
CA (1) CA2143491C (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100719080B1 (ko) * 1996-11-01 2007-05-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 사이토킨에 대한 세포반응을 조절하는 치료 및 진단 시약

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US6359194B1 (en) 1995-02-10 2002-03-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US6099823A (en) * 1996-02-16 2000-08-08 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
EP0904277A4 (en) 1996-02-16 2003-01-22 Millennium Pharm Inc COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CARDIOVASCULAR DISEASES
US6046000A (en) * 1997-11-07 2000-04-04 Millennium Biotherapeutics, Inc. Method for identifying genes encoding signal sequences
JP5004390B2 (ja) 1999-08-23 2012-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 新規ｂ７−４分子およびその用途
US6808710B1 (en) * 1999-08-23 2004-10-26 Genetics Institute, Inc. Downmodulating an immune response with multivalent antibodies to PD-1
WO2001034469A2 (en) * 1999-11-09 2001-05-17 Colombo Edward A Packaging system for preserving perishable items
US20010053769A1 (en) 2000-01-21 2001-12-20 Christiane Ferran Use of pro-apoptotic factors in treatment of atherosclerosis
US20020164600A1 (en) * 2000-06-28 2002-11-07 Gordon Freeman PD-L2 molecules: novel PD-1 ligands and uses therefor
US7414171B2 (en) * 2000-11-15 2008-08-19 Ono Pharmaceutical Co., Ltd. PD-1-lacking mouse and use thereof
US6842454B2 (en) * 2001-03-14 2005-01-11 Schneider Automation Inc. Method and system for device addressing on a computer network
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
NZ528265A (en) 2001-04-02 2005-10-28 Wyeth Corp Screening of compounds which modulate PD-1 signalling by testing for compounds that modulate phosphorylation of SHP-2, ERK1 or ERK-2, and PKC-theta
US20040241745A1 (en) * 2001-07-31 2004-12-02 Tasuku Honjo Substance specific to pd-1
US20040033497A1 (en) * 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
WO2003042402A2 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
US7521051B2 (en) * 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US7892540B2 (en) 2004-10-06 2011-02-22 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
NZ564243A (en) 2005-06-08 2011-03-31 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
NZ626867A (en) * 2006-12-27 2014-09-26 Harvard College Compositions and methods for the treatment of infections and tumors
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
JP5945096B2 (ja) * 2008-07-04 2016-07-05 小野薬品工業株式会社 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
CA2738252C (en) 2008-09-26 2018-05-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
SI4209510T1 (sl) 2008-12-09 2024-04-30 F. Hoffmann-La Roche Ag Protitelesa anti-PD-L1 in njihova uporaba za izboljšanje funkcije celic T
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
WO2011097511A1 (en) 2010-02-05 2011-08-11 The United States Of America, As Represented By The Secretary Department Of Health & Human Services REGULATORY B CELLS (tBREGS) AND THEIR USE
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US9783578B2 (en) 2010-06-25 2017-10-10 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013122262A1 (en) 2012-02-16 2013-08-22 Vlp Therapeutics, Llc Virus like particle composition
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
EP2879710B1 (en) 2012-08-03 2019-11-13 Dana-Farber Cancer Institute, Inc. Medical uses of agents that modulate immune cell activation and corresponding screening methods
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP3831840A1 (en) 2013-03-15 2021-06-09 Celgene Corporation Modified t lymphocytes
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
DK3044234T3 (da) 2013-09-13 2020-05-18 Beigene Switzerland Gmbh Anti-PD1-antistoffer og anvendelse deraf som terapeutika og diagnostika
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP3094736A4 (en) 2014-01-14 2017-10-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015249374A1 (en) 2014-04-24 2016-12-01 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
SG11201609638RA (en) 2014-06-19 2016-12-29 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
KR102003754B1 (ko) 2014-07-03 2019-07-25 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
SG11201700496WA (en) 2014-07-22 2017-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
KR102357893B1 (ko) 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
MX2017001597A (es) 2014-08-05 2017-11-17 Cb Therapeutics Inc Anticuerpos anti-pd-l1.
US10800830B2 (en) * 2014-08-08 2020-10-13 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106687590B (zh) 2014-09-11 2021-08-03 Vlp治疗公司 黄热病毒病毒样颗粒
BR112017004826A2 (pt) 2014-09-13 2017-12-12 Novartis Ag terapias de combinação de inibidores de alk
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016144673A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3365062B1 (en) 2015-10-19 2024-09-18 CG Oncology, Inc. Methods of treating solid or lymphatic tumors by combination therapy
DK3394103T5 (da) 2015-12-22 2024-09-30 Regeneron Pharma Kombination af anti-PD-1-antistoffer og bispecifikke anti-CD20-/anti-CD3-antistoffer til cancerbehandling
CN109311981B (zh) 2016-01-22 2022-08-23 马布奎斯特公司 Pd1特异性抗体
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
AU2017238054B2 (en) 2016-03-21 2023-10-19 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
TWI786044B (zh) 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
WO2018001241A1 (zh) * 2016-06-28 2018-01-04 北京百奥赛图基因生物技术有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CN118252927A (zh) 2016-08-19 2024-06-28 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
SI3512547T1 (sl) 2016-09-14 2021-01-29 Abbvie Biotherapeutics Inc. Anti-PD-1 protitelesa
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
JP2019531284A (ja) 2016-09-19 2019-10-31 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法
WO2018084706A1 (en) * 2016-11-04 2018-05-11 Erasmus University Medical Center Rotterdam Markers for identifying patient classes and use thereof
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
EP3634496A4 (en) 2017-06-06 2021-09-08 Dana-Farber Cancer Institute, Inc. METHOD FOR RISING AWARENESS IN CANCER CELLS AGAINST T-CELL-MEDIATED KILLING BY MODULATING MOLECULAR SIGNAL PATHS
WO2018226336A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
AU2018290532A1 (en) 2017-06-26 2019-11-21 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
JP7244852B2 (ja) 2017-09-08 2023-03-23 学校法人産業医科大学 免疫機能評価方法およびその為のｅｌｉｓａシステム
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CN111757894A (zh) 2018-02-14 2020-10-09 Abba 疗法股份公司 抗人类pd-l2抗体
US11629179B2 (en) 2018-06-29 2023-04-18 Stichting Het Nederlands Kanker Instituut—Antoni van Leeuwenhoek Ziekenhuis TWEAK-receptor agonists for use in combination with immunotherapy of a cancer
JP2022513113A (ja) 2018-11-26 2022-02-07 マサチューセッツ インスティテュート オブ テクノロジー 免疫寛容のための組成物および方法
WO2020223121A1 (en) 2019-04-30 2020-11-05 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
WO2021151974A1 (en) 2020-01-28 2021-08-05 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Interfering with mrna splicing to enhance response to checkpoint immunotherapies.
JP2023524055A (ja) 2020-04-30 2023-06-08 ブイエルピー・セラピューティクス・インコーポレイテッド サイトカイン免疫療法
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5336973A (en) * 1976-09-16 1978-04-05 Masakuni Kanai Method of recovering wasted can
JP3454275B2 (ja) * 1992-06-05 2003-10-06 佑 本庶 プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100719080B1 (ko) * 1996-11-01 2007-05-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 사이토킨에 대한 세포반응을 조절하는 치료 및 진단 시약

Also Published As

Publication number Publication date
CN1113518A (zh) 1995-12-20
JPH07291996A (ja) 1995-11-07
EP0670369A2 (en) 1995-09-06
JP2003230395A (ja) 2003-08-19
US5698520A (en) 1997-12-16
CN1080311C (zh) 2002-03-06
KR100391227B1 (ko) 2003-10-22
CA2143491C (en) 2011-02-22
US5629204A (en) 1997-05-13
CA2143491A1 (en) 1995-09-02
EP0670369A3 (en) 1998-09-02

Similar Documents

Publication Publication Date Title
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
Itoh et al. Extensible and less-extensible domains of connectin filaments in stretched vertebrate skeletal muscle sarcomeres as detected by immunofluorescence and immunoelectron microscopy using monoclonal antibodies
Creighton The single-disulphide intermediates in the refolding of reduced pancreatic trypsin inhibitor
KR960705850A (ko) 사람 쿠니즈형 프로테아제 저해인자(human kunitz-type protease inhibitors)
Nakada et al. Elucidation of an essential structure recognized by an anti-GalNAc alpha-Ser (Thr) monoclonal antibody (MLS 128)
KITAHARA et al. Large-scale purification of porcine calpain I and calpain II and comparison of proteolytic fragments of their subunits
Akiyama et al. The amino acid sequence of human β-microseminoprotein
BR9507594A (pt) Processo para o tratamento de glomerulonefrite em um paciente necessitado deste tratamento artigo de fabricação anticorpo hibridoma 5g.1;1 molécula deácido nucleico proteina isolada polipeptideo isolado vetor de ácido nucleico célula hospedeira recombinante processo para produzir um polipeptideo de anticorpo c5 isolado anticorpo anti-c5 isolado processo para produzir uma proteina de anticorpo anti-c5 isolado molécula de ácido nucleico isolada processo para produzir um anticorpo anti-c5 anticorpo anti-c5 fragmento 5g46k fragmento 5g27k peptideo 5g325aa isolado peptideo 5g200aa isolado oligopeptideo isolado processo para induzir um animal a produzir um anti-c5 processo para identificar um anticorpo anti-c5 e processo para tratar um paciente necessitado de inibiçao complemetar
Tsuruta et al. Structural analysis of sulphated glycoprotein 2 from amino acid sequence. Relationship to clusterin and serum protein 40, 40
KR960704038A (ko) 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)
ATE159727T1 (de) Kleinste erkennungseinheit eines pem-mucin- ''tandem repeat''-spezifischen monoklonalen antikoerpers
KR970707153A (ko) 카텝신 02 프로테아제(cathepsin 02 protease)
EA199800046A1 (ru) Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента
Riseman et al. The calmodulin and F-actin binding sites of smooth muscle caldesmon lie in the carboxyl-terminal domain whereas the molecular weight heterogeneity lies in the middle of the molecule
ATE132197T1 (de) Monoklonale antikörper
RU2218181C2 (ru) ЧЕЛОВЕЧЕСКИЙ СЕМАФОРИН L(H-Sema-L) И СООТВЕТСТВУЮЩИЕ СЕМАФОРИНЫ В ДРУГИХ ВИДАХ
Amano et al. Binding of Porphyromonas gingivalis fimbriae to proline-rich glycoproteins in parotid saliva via a domain shared by major salivary components
RU98112759A (ru) Человеческий семафорин l (h-sema-l) и соответствующие семафорины в других видах
KR970707162A (ko) II종 포스포리파제 A2 저해작용을 갖는 신규한 모노클로날 항체 및 그 일부를 포함하는 단백질(Novel monoclonal antibody having inhibitory effect on type II phospholipase A2 and protein containing a part of the same)
Sledge et al. Antibody structure: amino terminal sequences of nurse shark light and heavy chains
KR920012440A (ko) 인간 인터류킨-5 수용체
DE3884316D1 (de) Synthetische Peptide, gegen diese gerichtete Antikörper und deren Verwendung.
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
Jacob et al. Altered cell-surface protein (s), crossreactive with DNA, on spleen cells of autoimmune lupic mice.
Thomas et al. Identification and alignment of a thiol ester site in the third component of guinea pig complement

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130621

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20140626

Year of fee payment: 12